Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens

References

• Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010;23:133–143.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM. Ofatumumab in the treatment of chronic lymphocytic leukemia. Drugs Today (Barc) 2010;46:451–461.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725–733.
   PubMed Web of Science ®Google Scholar
• Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106:376–383.
   PubMed Web of Science ®Google Scholar
• Kruschinski A, Moosmann A, Poschke I, . Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci USA 2008;105:17481–17486.
   PubMed Web of Science ®Google Scholar
• Uherek C, Tonn T, Uherek B, . Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002;100:1265–1273.
   PubMed Web of Science ®Google Scholar
• Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136–1151.
   PubMed Web of Science ®Google Scholar
• Verheyden S, Demanet C. NK cell receptors and their ligands in leukemia. Leukemia 2008;22:249–257.
   PubMed Web of Science ®Google Scholar
• Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011;132:315–325.
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, . Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051–3057.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Capanni M, . Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110:433–440.
   PubMed Web of Science ®Google Scholar
• Spanholtz J, Preijers F, Tordoir M, . Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One 2011;6:e20740.
   PubMed Web of Science ®Google Scholar
• Micucci F, Zingoni A, Piccoli M, . High-efficient lentiviral vector-mediated gene transfer into primary human NK cells. Exp Hematol 2006;34:1344–1352.
   PubMed Web of Science ®Google Scholar
• Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994;8:652–658.
   PubMed Web of Science ®Google Scholar
• Yan Y, Steinherz P, Klingemann HG, . Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 1998;4:2859–2868.
   PubMed Web of Science ®Google Scholar
• Maki G, Klingemann HG, Martinson JA, . Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res 2001;10:369–383.
   PubMedGoogle Scholar
• Tonn T, Becker S, Esser R, . Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001;10:535–544.
   PubMed Web of Science ®Google Scholar
• Arai S, Meagher R, Swearingen M, . Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008;10:625–632.
   PubMed Web of Science ®Google Scholar
• Romanski A, Bug G, Becker S, . Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol 2005;33:344–352.
   PubMed Web of Science ®Google Scholar
• Romanski A, Uherek C, Bug G, . Re-targeting of an NK cell line (NK92) with specificity for CD19 efficiently kills human B-precursor leukemia cells. Blood 2004;104(Suppl. 1): Abstract 2747.
   Google Scholar
• Boissel L, Betancur M, Wels WS, . Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res 2009;33:1255–1259.
   PubMed Web of Science ®Google Scholar
• Müller T, Uherek C, Maki G, . Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 2008;57:411–423.
   PubMed Web of Science ®Google Scholar
• D'Costa J, Mansfield SG, Humeau LM. Lentiviral vectors in clinical trials: current status. Curr Opin Mol Ther 2009;11:554–564.
   PubMed Web of Science ®Google Scholar
• Matrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol Ther 2010;18: 477–490.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, . T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
   Web of Science ®Google Scholar
• Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003;4:346–358.
   PubMed Web of Science ®Google Scholar
• Li L, Liu LN, Feller S, . Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther 2010;17:147–154.
   PubMed Web of Science ®Google Scholar
• Tohda S, Sakashita C, Fukuda T, . Establishment of a double Philadelphia chromosome-positive acute lymphoblastic leukemia-derived cell line, TMD5: effects of cytokines and differentiation inducers on growth of the cells. Leuk Res 1999;23:255–261.
   PubMed Web of Science ®Google Scholar
• Boissel L, Tuncer HH, Betancur M, . Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant 2008;14:1031–1038.
   PubMed Web of Science ®Google Scholar
• Weitzman J, Betancur M, Boissel L, . Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:1361–1368.
   PubMed Web of Science ®Google Scholar
• Williams BA, Wang XH, Keating A. Clonogenic assays measure leukemia stem cell killing not detectable by chromium release and flow cytometric cytotoxicity assays. Cytotherapy 2010;12:951–960.
   PubMed Web of Science ®Google Scholar
• Klingemann HG. Natural killer cell-based immunotherapeutic strategies. Cytotherapy 2005;7:16–22.
   PubMed Web of Science ®Google Scholar
• Berry LJ, Moeller M, Darcy PK. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens 2009;74:277–289.
   PubMed Web of Science ®Google Scholar
• Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2011;116:1035–1044.
   Web of Science ®Google Scholar
• Kochenderfer JN, Wilson WH, Janik JE, . Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099–4102.
   PubMed Web of Science ®Google Scholar
• D'Arena G, Dell'Olio M, Musto P, . Morphologically typical and atypical B-cell chronic lymphocytic leukemias display a different pattern of surface antigenic density. Leuk Lymphoma 2001;42:649–654.
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Matutes E, . Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998;51: 364–369.
   PubMed Web of Science ®Google Scholar
• Berg M, Lundqvist A, McCoy P Jr, . Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009;11:341–355.
   PubMed Web of Science ®Google Scholar
• Klingemann HG, Martinson J. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy 2004;6:15–22.
   PubMed Web of Science ®Google Scholar
• Berg M, Childs R. Ex-vivo expansion of NK cells: what is the priority—high yield or high purity?. Cytotherapy 2010;12:969–970.
   PubMed Web of Science ®Google Scholar